
11 - 50 employees
Founded 2019
🏥 Healthcare
🏭 Manufacturing
🧬 Biotechnology
💰 $75M Series D - Spyglass Pharma on 2025-06
Healthcare • Manufacturing • Biotechnology
<SpyGlass Pharma, Inc. > SpyGlass Pharma, Inc. is a clinical-stage company developing the BIM-IOL System, a sustained drug-delivery intraocular lens designed to deliver long-acting glaucoma therapy at the time of cataract surgery. The technology integrates glaucoma treatment with a trusted surgical procedure to address gaps in adherence and chronic disease management, and the company is advancing the device through preclinical studies and clinical trials (first-in-human, Phase 1/2, and Phase 3).
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 August 21
Medical Science Liaison supporting SpyGlass Pharma’s Phase 3 ophthalmic drug-delivery trials. Engaging investigators and sites across the U.S. to advance glaucoma treatment.
🇺🇸 United States – Remote
💵 $175k - $225k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 0%
🕒 August 21
Medical Science Liaison supporting SpyGlass Pharma’s Phase 3 ophthalmic drug delivery trials. Engaging investigators and sites across the United States.
🇺🇸 United States – Remote
💵 $175k - $225k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 0%
🕒 August 21
Medical Science Liaison supporting SpyGlass Pharma’s Phase 3 ophthalmic drug-delivery trials. Engaging investigators, sites, and healthcare providers across a U.S. territory.
🇺🇸 United States – Remote
💵 $175k - $225k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🟡 Mid-level
🟠 Senior
👻 Ghost score 0%
🕒 August 21
Regional medical affairs director advancing SpyGlass Pharma’s ophthalmic drug-delivery programs through Phase 3 trials. Leading scientific engagement with ophthalmology investigators, providers, and strategic healthcare accounts.
🇺🇸 United States – Remote
💵 $225k - $250k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 0%
🕒 August 21
Regional MSL Director leading scientific engagement for SpyGlass Pharma’s ophthalmic drug-delivery programs. Supporting Phase 3 trials, investigator relationships, and glaucoma-focused medical affairs across the United States.
🇺🇸 United States – Remote
💵 $225k - $250k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 0%
🕒 August 21
Regional MSL Director advancing SpyGlass Pharma’s ophthalmic drug-delivery therapies through Phase 3 development. Leading scientific engagement across U.S. ophthalmology and glaucoma networks.
🇺🇸 United States – Remote
💵 $225k - $250k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 0%